Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Clinical Considerations for RET Fusion–Positive NSCLC

Source: ClinicalImpact™ RET-Altered or RET-Driven NSCLC and Thyroid Cancer: Expert Guidance for Improving Outcomes

Listen to lung cancer experts Joshua Bauml, MD, a medical oncologist, and Dara L. Aisner, MD, PhD, a molecular pathologist, discuss clinical considerations for patients with RET fusion–positive NSCLC, including testing for RET fusions, using new selective RET inhibitors in these patients, and the importance of interdisciplinary communication.

Dara L. Aisner, MD, PhD
Joshua Bauml, MD
Released: September 17, 2020

In this podcast episode, listen to lung cancer experts Joshua Bauml, MD, a medical oncologist, and Dara L. Aisner, MD, PhD, a molecular pathologist, discuss clinical considerations for patients with RET fusion–positive NSCLC, with topics including:

  • Optimal testing for RET fusions
  • DNA NGS vs RNA NGS
  • Molecular testing workflows
  • Using new selective RET inhibitors to treat patients with RET fusion–positive NSCLC
  • Common toxicities with new selective RET inhibitors
  • Interdisciplinary communication between medical oncologists and pathologists

Link to full program, including associated downloadable slidesets:
https://www.clinicaloptions.com/oncology/programs/ret-positive-cancers

Acknowledgements

Provided by Clinical Care Options, LLC.
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Lilly

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Related Content

Read expert insights on best practices for incorporating immune checkpoint inhibitor therapy for patients with NSCLC, from Clinical Care Options (CCO)

Julie R. Brahmer, MD
Program Director person default Jarushka Naidoo, MB BCH BAO, MHS Zofia Piotrowska, MD, MHS Released: January 23, 2023

On-demand webcast from a live satellite symposium at SITC 2022 on current use of IO therapy in lung cancer, from Clinical Care Options (CCO)

Julie R. Brahmer, MD
Program Director person default Jarushka Naidoo, MB BCH BAO, MHS Zofia Piotrowska, MD, MHS Physicians: maximum of 1.5 AMA PRA Category 1 Credits™ Released: January 17, 2023 Expired: January 16, 2024

Downloadable slideset from a workshop series from Clinical Care Options (CCO) on the management of NTRK and RET-altered lung and thyroid cancer

person default Saad A. Khan, MD Sandip P. Patel, MD Released: November 17, 2022

Experts provide their thoughts on key data in breast, gynecologic, renal cell, urothelial, lung, hepatobiliary, and skin cancers presented at the 2022 ESMO Congress, from Clinical Care Options (CCO)

Nicoletta Colombo, MD Robert Motzer, MD person default Sapna P. Patel, MD David Planchard, MD, PhD Elizabeth R. Plimack, MD, MS Rachna Shroff, MD, MS Sara Tolaney, MD, MPH Physicians: maximum of 1.25 AMA PRA Category 1 Credits™ Released: November 14, 2022 Expired: November 13, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings